“From the Research Bench to the Market: Overcoming Some of the Challenges Facing Biotech and Pharmaceutical Development in the 21st Century”
Today’s drug discovery enterprise is fast paced, highly competitive, and rapidly evolving. The biotechnology and pharmaceutical industries have experienced rapid advances in science and technology, a surge in mergers, acquisitions and strategic alliances, and unprecedented globalization of the industry. As a consequence, the drug development industry is unbundling, providing new, global, opportunities for scientists and entrepreneurs. Success in this evolving field requires scientific expertise, along with an appreciation for the business and legal context of drug discovery and development. Only with a complete understanding will biopharmaceutical scientists and entrepreneurs be able to take advantage of the alternatives available for achieving proof of concept for their technologies. Dr Dennis Liotta will share his insight on the drug development process and how scientists and inventors can most effectively bring their research to the marketplace in the current environment.
Dr Dennis Liotta is an experienced researcher, pharmaceutical advisor and inventor. Dr Liotta is the Executive Director of the Emory Institute for Drug Discovery and the Samuel Candler Dobbs Professor of Chemistry at Emory University. He is a skilled researcher and veteran of the drug discovery and development process with over two hundred research publications and approximately seventy issued US patents. Over the past twenty-five years he has served as a consultant to many major pharmaceutical firms, including Merck, Glaxo, Burroughs Wellcome, Boehringer Ingelheim and Johnson & Johnson. He serves on the Scientific Advisory Boards (SABs) of several small biopharmaceutical companies including Altiris (scientific founder), Pharmasset (scientific founder), iThemba Pharmaceuticals (scientific founder, SAB Chair), NeurOp, and FOB Synthesis. He is also on the Board of Directors of Achillion Pharmaceuticals. In addition, he is the inventor of record for several clinically important agents, including FTC (Emtriva®, Emtricitabine), 3TC (Epivir®, Lamivudine), Reverset® (DPC 817, D-D4FC), Racivir® ((+/-)-FTC), Elvucitabine® (L-D4FC) and MSX-122. His business, research, and corporate activities span multiple continents, as well as varied political and legal environments.
(Buffet dinner reception will be served after the talk) Venue: Ngee Ann Kongsi Auditorium, Level 2, (School of Accountancy /School of Law), SMU
60 Stamford Road, Singapore 178900 (Map)